A major investment firm upgraded Cencora's rating from Hold to Buy, signaling fresh confidence in the logistics and pharmaceutical distribution player. The new price target jumped to $440 from $330—a meaningful shift that caught market attention. The 33% upside represents analysts' belief that the company has stronger fundamentals or growth prospects than previously assessed. For investors tracking supply chain plays and distribution networks in the healthcare space, this kind of catalytic upgrade often marks institutional conviction building. Whether this reflects operational improvements or sector tailwinds remains worth digging into.